TPST · NASDAQ
Tempest Therapeutics (TPST) Stock Price & Fundamentals
Tempest Therapeutics (TPST) closed at $1,083.28 on Oct 9, 2026, up 1.49% from the previous close of $1,067.33.
Share price, past year
1Y +83.32%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,083.28 |
| Sep 30, 2026 | $1,070.97 |
| Aug 31, 2026 | $986.96 |
| Jul 31, 2026 | $926.16 |
| Jun 30, 2026 | $892.67 |
| May 29, 2026 | $863.18 |
| Apr 30, 2026 | $821.40 |
| Mar 31, 2026 | $796.66 |
| Feb 27, 2026 | $792.58 |
| Jan 30, 2026 | $759.61 |
| Dec 31, 2025 | $697.23 |
| Nov 28, 2025 | $654.18 |
| Oct 31, 2025 | $600.43 |
Key statistics
- Market cap
- $17.31B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- −$40.47M
- Shares outstanding
- 16M
- Dividend yield
- —
- 52-week range
- $590.92 – $1,083.28
Tempest Therapeutics's market cap is $17.31B, based on a share price of $1,083.28 and 16M shares outstanding as of Jun 30, 2026.
Financials
Tempest Therapeutics reported revenue of $295.00K for fiscal 2017, down 54.82% from fiscal 2016.
Tempest Therapeutics reported a net loss of $26.26M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2017ended Dec 31, 2017 | $295.00K | −54.8% | −$84.58M | −28,670.5% | — | −$20.34M |
| FY2016ended Dec 31, 2016 | $653.00K | +135.7% | −$82.26M | −12,597.2% | — | −$64.32M |
| FY2015ended Dec 31, 2015 | $277.00K | — | — | — | — | — |
| FY2014ended Dec 31, 2014 | $0.00 | — | — | — | — | — |
| FY2013ended Dec 31, 2013 | $0.00 | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q3 FY2018ended Sep 30, 2018 | $55.00K | — | — |
| Q2 FY2018ended Jun 30, 2018 | $81.00K | — | — |
| Q1 FY2018ended Mar 31, 2018 | $67.00K | — | — |
| Q4 FY2017ended Dec 31, 2017 | $92.00K | — | — |
| Q3 FY2017ended Sep 30, 2017 | $56.00K | — | — |
| Q2 FY2017ended Jun 30, 2017 | $84.00K | — | — |
| Q1 FY2017ended Mar 31, 2017 | $63.00K | — | — |
| Q4 FY2016ended Dec 31, 2016 | $121.00K | — | — |
Company profile
- Name
- Tempest Therapeutics, Inc.
- Ticker
- TPST
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001544227
Recent SEC filings
- Sep 28, 2026
- Sep 17, 2026
- Sep 16, 2026
- Sep 15, 2026
- Aug 24, 2026
- Aug 18, 2026
- Aug 13, 2026
- Aug 13, 2026
Frequently asked questions
What is Tempest Therapeutics's stock price?
Tempest Therapeutics (TPST) closed at $1,083.28 on Oct 9, 2026, up 1.49% from the previous close of $1,067.33.
What is Tempest Therapeutics's market cap?
Tempest Therapeutics's market cap is $17.31B, based on a share price of $1,083.28 and 16M shares outstanding as of Jun 30, 2026.
How much revenue does Tempest Therapeutics make?
Tempest Therapeutics reported revenue of $295.00K for fiscal 2017, down 54.82% from fiscal 2016.
Does Tempest Therapeutics pay a dividend?
Tempest Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Tempest Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures